15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $66M | -$14M | 69.0% | -11.8% | -$2M | $13M | $31M |
| 2024 | $65M | -$16M | 75.3% | -2.4% | -$2M | $15M | $20M |
| 2023 | $107M | -$17M | 62.0% | -15.9% | — | $17M | $23M |
| 2022 | $97M | -$109M | 54.1% | -113.7% | — | $19M | $19M |
| 2021 | $66M | -$58M | 44.5% | -89.7% | — | — | $50M |
| 2020 | $28M | -$14M | 70.0% | -76.5% | -$28M | — | $48M |
| 2019 | — | -$27M | — | — | -$14M | $0 | $11M |
| 2018 | — | -$10M | — | — | -$16M | $0 | $7M |
| 2017 | — | -$23M | — | — | -$14M | — | $802328 |
| 2016 | — | -$28M | — | — | — | — | $8M |
| 2015 | — | -$8M | — | — | — | — | $7M |
| 2014 | — | -$61723 | — | — | — | — | — |
| 2014 | — | -$6M | — | — | — | — | $3M |
| 2014 | — | -$618731 | — | — | -$379969 | — | — |
| 2014 | — | -$606907 | — | — | -$365554 | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $12M | -$6M | 61.2% | -32.7% | -$4M | $11M | $27M |
| Dec '25 | $15M | -$11M | 63.5% | -13.0% | $4M | $12M | $30M |
| Sep '25 | $14M | $2M | 66.1% | -10.8% | -$618000 | $12M | $33M |
| Jun '25 | $15M | -$20M | 67.8% | -50.4% | — | $13M | $31M |
| Mar '25 | $18M | $4M | 69.4% | 13.1% | -$7M | $11M | $18M |
| Dec '24 | $16M | $788000 | 66.5% | -10.4% | $3M | $16M | $20M |
| Sep '24 | $17M | $1M | 72.3% | -5.6% | -$1M | $17M | $20M |
| Jun '24 | $15M | -$5M | 75.7% | -15.6% | — | $15M | $20M |
| Mar '24 | $14M | -$3M | 73.9% | -11.4% | — | $17M | $20M |
| Dec '23 | $19M | -$220000 | 77.9% | 16.8% | — | $16M | $20M |
| Sep '23 | $18M | -$8M | 73.2% | -4.9% | — | $16M | $20M |
| Jun '23 | $31M | -$2M | 60.4% | 0.5% | — | $17M | $23M |
| Mar '23 | $23M | -$7M | 56.1% | -37.6% | — | $25M | $19M |
| Dec '22 | $26M | -$7M | 65.8% | -26.1% | — | $22M | $20M |
| Sep '22 | $28M | -$701000 | 65.2% | -6.5% | — | $15M | $24M |
| Jun '22 | $27M | -$16M | 54.1% | -61.7% | — | $19M | $19M |
| Mar '22 | $24M | -$53M | 52.4% | -220.8% | — | $15M | $28M |
| Dec '21 | $23M | -$12M | 53.2% | -48.8% | — | — | $35M |
| Sep '21 | $22M | -$28M | 56.9% | -126.5% | — | — | $40M |
| Jun '21 | $23M | -$19M | 48.1% | -102.5% | — | — | $50M |
How the market has priced AYTU against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, AYTU BIOPHARMA, INC's revenue has grown 19.2% per year. These are computed facts, not advice.
As of FY2025, AYTU BIOPHARMA, INC reported $13M of total debt against $31M of cash; operating income covered interest expense -2.1×.
In FY2025, gross margin was 69.0%, operating margin -11.8%, and net margin -20.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.